The AspECT EXceL study aims to continue to follow up the AspECT study participants to see if esomeprazole effectiveness continues or increases long-term and investigate the long-term benefits and risks of using esomeprazole with or without aspirin in reducing the risk of cancer

Phase 4

• Conditions: Barrett's oesophagus (BO); Digestive System; Barrett oesophagus

• Registration Number: ISRCTN14949833
• Lead Sponsor: niversity College London Comprehensive Clinical Trials Unit (UCL CCTU)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-22
• Last Update Posted: 5 February 2024
• Study Completion: 2025-05-29

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1587

Inclusion Criteria

1. Participants recruited to the original AspECT trial
2. AspECT participants who have signed an AspECT-EXceL consent form or have the use of personal data covered by another access agreement
3. Participants who have given consent to allow access to AspECT data or have access covered by another access agreement

Exclusion Criteria

1. Participants who are alive and unable or unwilling to give consent to participate in AspECT ExceL and whose personal data is not covered by any other data access agreement
2. Participants unwilling to give consent to allow access to AspECT data and are not covered by any other data access agreement
3. Participants not included in the original AspECT trial

Study & Design

• Study Type: Observational
• Study Design: Not specified